BWLSA
PACB icon

Blue Water Life Science Advisors’s Pacific Biosciences PACB Stock Holding History

Blue Water Life Science Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,660,000
Closed -$24.2M – 11
2022
Q1 		$24.2M Buy
+2,660,000
New +$30.6M 11.49% 4

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Blue Water Life Science Advisors's PACB Position: Q2 2022 in Review

Blue Water Life Science Advisors sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 2,660,000 shares — an estimated $24.2M sold.

Blue Water Life Science Advisors first reported a position in PACB in Q1 2022 and held it in 1 quarter. The position peaked at $24.2M in Q1 2022. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

  • Blue Water Life Science Advisors reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
  • Blue Water Life Science Advisors sold 2,660,000 Pacific Biosciences shares in Q2 2022, an estimated $24.2M.
  • Blue Water Life Science Advisors first reported a position in Pacific Biosciences in Q1 2022 and held it in 1 quarter.
  • Blue Water Life Science Advisors's Pacific Biosciences position peaked at $24.2M in Q1 2022.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Blue Water Life Science Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.